Overview Energy plans to collect sunlight in orbit and send it to Earth, giving Meta early access to a new source of round-the-clock power
Updated
April 29, 2026 3:20 PM
A corona mass ejection erupts from our sun. PHOTO: UNSPLASH
Overview Energy, a startup focused on space-based power systems, has announced a new agreement with Meta to develop a new source of electricity for data centers. The partnership centres on space solar energy, with an orbital demonstration planned for 2028 and commercial power delivery targeted for 2030.
The deal gives Meta early access to as much as 1 gigawatt of future capacity from Overview’s system. That matters because large technology companies are searching for reliable power sources as demand rises from AI computing and data center expansion.
Overview’s idea is straightforward, though the engineering is ambitious. The company plans to place satellites in orbit that collect sunlight continuously in space. That energy would then be sent to existing solar sites on Earth, where it would be converted into electricity.
Unlike ground-based solar farms, which only generate power when the sun is shining locally, a space-based system is designed to extend power generation beyond daylight hours. In theory, this could help solar facilities produce electricity around the clock without using extra land.
"Space solar technology represents a transformative step forward by leveraging existing terrestrial infrastructure to deliver new, uninterrupted energy from orbit. We're excited to partner with Overview Energy to pioneer innovative energy solutions to advance our AI ambitions and infrastructure", said Nat Sahlstrom, VP of Energy and Sustainability, Meta. "This collaboration demonstrates our commitment to innovation – leveraging cutting-edge technology to strengthen America's energy leadership".
For Meta, the agreement is less about a near-term energy fix and more about securing future options. Major data center operators are increasingly competing for electricity as AI systems require more computing power and more cooling capacity. Traditional energy projects can take years to build, making alternative supply models more attractive.
Overview says its system is designed to work with solar projects that already exist. Instead of building entirely new power plants, the company aims to increase output from current sites by adding energy received from orbit.
"Space is becoming part of America's energy infrastructure", said Marc Berte, CEO of Overview Energy. "Our approach to space solar energy enables hyperscalers and technology providers to secure clean power with reliable siting, and speed to power.” "Together with Meta, we're looking beyond traditional constraints on where and when power can be delivered to meet the growing demand for electricity".
The larger significance of the partnership is what it signals about the energy market. As AI infrastructure expands, companies are beginning to look beyond conventional grids, gas plants and land-based renewables. Technologies once considered experimental are now being explored as part of long-term infrastructure planning.
There is still a long road ahead. Space solar power has been discussed for decades, but commercial deployment remains unproven. Launch costs, regulation and system reliability will all matter.
Even so, the Meta-Overview agreement shows how rising demand for constant power is reshaping where the technology sector looks for its next energy source.
Keep Reading
A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.